The European Union s health regulator gave its nod for the use of Pfizer s COVID anti viral pill on Thursday In a statement the European Medicines Agency EMA said it had recommended authorising Paxlovid for treating COVID in adults who are at increased risk of the disease becoming severe Paxlovid has so far been authorised for people aged and older in a handful of countries including the United States Canada and Israel The European Union had allowed member states to use it ahead of formal approval as an emergency measure against Omicron reports news agency AFP The drug which comprises two types of tablet is the first COVID therapy which can be taken at home It is usually prescribed to high risk patients from getting so sick that they need to be hospitalised It is taken twice a day for five days in combination with a second medicine called ritonavir a generic antiviral Unlike vaccines it does not target the ever evolving spike protein which the coronavirus uses to invade cells The company in its preliminary lab studies concluded that the pill in theory is more variant proof than the vaccines In a Pfizer study involving more than people at high risk for developing serious COVID it was found that Paxlovid reduced the risk of hospitalisation or death by per cent compared with a placebo when taken within three days of first symptoms of illness When taken within five days the drug reduced the risk of hospitalisation and death by per cent the study conducted by the company claimed Source WION